SWM
DNA icon

Silverlake Wealth Management’s Ginkgo Bioworks DNA Stock Holding History

Silverlake Wealth Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-375
Closed -$5.01K – 279
2024
Q2 		$5.01K Hold
375
– – ﹤0.01% 282
2024
Q1 		$17.4K Hold
375
– – 0.01% 240
2023
Q4 		$25.4K Hold
375
– – 0.01% 226
2023
Q3 		$27.1K Hold
375
– – 0.02% 225
2023
Q2 		$27.9K Hold
375
– – 0.02% 226
2023
Q1 		$19.9K Hold
375
– – 0.01% 214
2022
Q4 		$25.4K Buy
+375
New +$34.5K 0.02% 212

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Silverlake Wealth Management's DNA Position: Q3 2024 in Review

Silverlake Wealth Management sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 375 shares — an estimated $5.01K sold.

Silverlake Wealth Management first reported a position in DNA in Q4 2022 and held it in 7 quarters. The position peaked at $27.9K in Q2 2023. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Silverlake Wealth Management reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Silverlake Wealth Management sold 375 Ginkgo Bioworks shares in Q3 2024, an estimated $5.01K.
  • Silverlake Wealth Management first reported a position in Ginkgo Bioworks in Q4 2022 and held it in 7 quarters.
  • Silverlake Wealth Management's Ginkgo Bioworks position peaked at $27.9K in Q2 2023.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Silverlake Wealth Management's 13F filing for Q3 2024, filed 10 Oct 2024.